Syntal Capital Partners, LLC Prothena Corp Public LTD CO Transaction History

Syntal Capital Partners, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 11, 2022	SELL	$42.11 - $73.26 $1.42 Million - $2.46 Million	-33,615 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $1.62 Million - $2.65 Million	33,615 New	33,615 $2.39 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Syntal Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Syntal Capital Partners, LLC with notifications on news.